amlexanox has been researched along with Libman-Sacks Disease in 1 studies
amlexanox: SRA-A antagonist;structure given in first source
amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Todd, I | 1 |
| Thomas, RE | 1 |
| Watt, BD | 1 |
| Sutherland, L | 1 |
| Afriyie-Asante, A | 1 |
| Deb, B | 1 |
| Joseph, B | 1 |
| Tighe, PJ | 1 |
| Lanyon, P | 1 |
| Fairclough, LC | 1 |
1 other study available for amlexanox and Libman-Sacks Disease
| Article | Year |
|---|---|
Multiple pathways of type 1 interferon production in lupus: the case for amlexanox.
Topics: A549 Cells; Aminopyridines; Animals; Humans; Interferon Type I; Lupus Erythematosus, Systemic; Metab | 2020 |